BACKGROUND: Cardiac allograft vasculopathy (CAV) is primarily immune-mediated. We investigated the role of cellular rejection in CAV development. METHODS: The study comprised 252 cardiac transplant recipients (mean age, 49.02 +/- 17.05 years; mean follow-up, 7.61 +/- 4.49 years). Total rejection score (TRS) based on the 2004 International Society of Heart and Lung Transplantation R grading system (0R = 0, 1R = 1, 2R = 2, 3R = 3) and any rejection score (ARS; calculated as 0R = 0, 1R = 1, 2R = 1; 3R = 1, or the number of rejections of any grade) were normalized for the total number of biopsy specimens. CAV was defined as coronary stenosis of 40% or more and/or distal pruning of secondary side branches. Thirty-two patients had undergone 3-dimensional intravascular ultrasound (IVUS) at baseline and with virtual histology (VH) IVUS at 24 months. RESULTS: In univariate analysis, 6-month TRS (hazard ratio [HR], 1.9; 95% confidence interval [CI], 0.99-3.90, p = 0.05) and ARS (HR, 2.22; 95% CI, 1.01-4.95; p = 0.047) were associated with increased risk of CAV. In multivariate analysis, 6-month TRS (HR, 2.84; 95% CI, 1.44-6.91, p = 0.02) was significantly associated with increased risk of CAV onset. The 12- and 24-month rejection scores were not risk factors for the onset of CAV. By Kaplan-Meier analysis, 6-month TRS exceeding 0.3 was associated with a significantly shorter time to CAV onset (p = 0.018). There was direct correlation (r = 0.44, p = 0.012) between TRS at 6 months and the percentage of necrotic core demonstrated by VH-IVUS at 24 months. CONCLUSION: Recurrent cellular rejection has a cumulative effect on the onset of CAV. The mechanism may be due to increased inflammation resulting in increased plaque burden suggesting a relationship between the immune basis of cellular rejection and CAV.
BACKGROUND:Cardiac allograft vasculopathy (CAV) is primarily immune-mediated. We investigated the role of cellular rejection in CAV development. METHODS: The study comprised 252 cardiac transplant recipients (mean age, 49.02 +/- 17.05 years; mean follow-up, 7.61 +/- 4.49 years). Total rejection score (TRS) based on the 2004 International Society of Heart and Lung Transplantation R grading system (0R = 0, 1R = 1, 2R = 2, 3R = 3) and any rejection score (ARS; calculated as 0R = 0, 1R = 1, 2R = 1; 3R = 1, or the number of rejections of any grade) were normalized for the total number of biopsy specimens. CAV was defined as coronary stenosis of 40% or more and/or distal pruning of secondary side branches. Thirty-two patients had undergone 3-dimensional intravascular ultrasound (IVUS) at baseline and with virtual histology (VH) IVUS at 24 months. RESULTS: In univariate analysis, 6-month TRS (hazard ratio [HR], 1.9; 95% confidence interval [CI], 0.99-3.90, p = 0.05) and ARS (HR, 2.22; 95% CI, 1.01-4.95; p = 0.047) were associated with increased risk of CAV. In multivariate analysis, 6-month TRS (HR, 2.84; 95% CI, 1.44-6.91, p = 0.02) was significantly associated with increased risk of CAV onset. The 12- and 24-month rejection scores were not risk factors for the onset of CAV. By Kaplan-Meier analysis, 6-month TRS exceeding 0.3 was associated with a significantly shorter time to CAV onset (p = 0.018). There was direct correlation (r = 0.44, p = 0.012) between TRS at 6 months and the percentage of necrotic core demonstrated by VH-IVUS at 24 months. CONCLUSION: Recurrent cellular rejection has a cumulative effect on the onset of CAV. The mechanism may be due to increased inflammation resulting in increased plaque burden suggesting a relationship between the immune basis of cellular rejection and CAV.
Authors: Tengfang Li; Zhongqiang Zhang; Joe G Bartolacci; Gaelen K Dwyer; Quan Liu; Lisa R Mathews; Murugesan Velayutham; Anna S Roessing; Yoojin C Lee; Helong Dai; Sruti Shiva; Martin H Oberbarnscheidt; Jenna L Dziki; Steven J Mullet; Stacy G Wendell; James D Wilkinson; Steven A Webber; Michelle Wood-Trageser; Simon C Watkins; Anthony J Demetris; George S Hussey; Stephen F Badylak; Hēth R Turnquist Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Richard J Boruta; Shelley D Miyamoto; Adel K Younoszai; Sonali S Patel; Bruce F Landeck Journal: Pediatr Cardiol Date: 2017-09-25 Impact factor: 1.655
Authors: Maria Nataatmadja; Margaret Passmore; Fraser D Russell; Sulistiana Prabowo; Amanda Corley; John F Fraser Journal: Lung Date: 2014-05-06 Impact factor: 2.584
Authors: Chelsey L King; Jennifer J Devitt; Timothy D G Lee; Camille L Hancock Friesen Journal: J Cardiothorac Surg Date: 2010-06-22 Impact factor: 1.637
Authors: Yan Topilsky; Eugenia Raichlin; Tal Hasin; Barry A Boilson; John A Schirger; Naveen L Pereira; Brooks S Edwards; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Manish J Gandhi; Simon Maltais; Soon J Park; Richard C Daly; Amir Lerman; Sudhir S Kushwaha Journal: Transplantation Date: 2013-03-27 Impact factor: 4.939